Issues surrounding orphan disease and orphan drug policies in Europe
- 264 Downloads
An orphan disease is a disease with a very low prevalence. Although there are 5000–7000 orphan diseases, only 50 orphan drugs (i.e. drugs developed to treat orphan diseases) were marketed in the EU by the end of 2008. In 2000, the EU implemented policies specifically designed to stimulate the development of orphan drugs. While decisions on orphan designation and the marketing authorization of orphan drugs are made at the EU level, decisions on drug reimbursement are made at the member state level. The specific features of orphan diseases and orphan drugs make them a high-priority issue for policy makers.
The aim of this article is to identify and discuss several issues surrounding orphan disease and drug policies in Europe.
The present system of orphan designation allows for drugs for non-orphan diseases to be designated as orphan drugs. The economic factors underlying orphan designation can be questioned in some cases, as a low prevalence of a certain indication does not equal a low return on investment for the drug across its indications. High-quality evidence about the clinical added value of orphan drugs is rarely available at the time of marketing authorization, due to the low number of patients. A balance must be struck between ethical and economic concerns. To this effect, there is a need to initiate a societal dialogue on this issue, to clarify what society wants and accepts in terms of ethical and economic consequences. The growing budgetary impact of orphan drugs puts pressure on drug expenditure. Indications can be extended for an orphan drug and the total prevalence across indications is not considered. Finally, cooperation needs to be fostered in the EU, particularly through a standardized approach to the creation and use of registries.
These issues require further attention from researchers, policy makers, health professionals, patients, pharmaceutical companies and other stakeholders with a view to optimizing orphan disease and drug policies in Europe.
KeywordsEnzyme Replacement Therapy Bosentan Orphan Drug Eculizumab Marketing Authorization
Financial support for this research was received from the Belgian Health Care Knowledge Centre, a state-funded research institution. The authors have no conflicts of interest that are directly relevant to the content of this article.
- 1.European Commission. European Commission Regulation (EC) no. 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000; L18/1 [online]. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf [Accessed 2010 Jun 30]
- 2.European Medicines Agency. Annual report of the European Medicines Agency 2007. London: European Medicines Agency, 2008Google Scholar
- 3.Denis A, Simoens S, Fostier C, et al. Health technology assessment policy governing orphan diseases and orphan medicines. Brussels: Belgian Health Care Knowledge Centre, 2009Google Scholar
- 5.European Medicines Agency. COMP report to the Commission in relation to article 10 of regulation 141 /2000 on orphan medicinal products. London: European Medicines Agency, 2007Google Scholar
- 7.European Medicines Evaluation Agency. Committee for Orphan Medicinal Products (COMP) [online]. Available from URL: http://www.ema.europa.eu/htms/general/contacts/COMP/COMP.html [Accessed 2009 Nov 24]
- 9.European Medicines Agency. Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Revatio. London: European Medicines Agency, 2009Google Scholar
- 10.European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical trials in small populations [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/ewp/8356105en.pdf [Accessed 2009 Nov 24]
- 11.European Organisation for Rare Diseases. EURORDIS position paper on the ‘centralised procedure for the scientific assessment of the therapeutic added value of orphan drugs’ [online]. Available from URL: http://www.eurordis.org/IMG/pdf/position-paper-EURORDIS-therapeutic-added-value-ODFeb08.pdf [Accessed 2009 Nov 23]
- 12.The Pharmaceutical Forum. Improving access to orphan medicines for all affected EU citizens [online]. Available from URL: http://ec.europa.eu/pharmaforum/docs/pricing_orphans_en.pdf [Accessed 2009 Nov 16]
- 13.Cleemput I, Neyt M, Thiry N, et al. Cost-effectiveness thresholds in health care. Brussels: Belgian Healthcare Knowledge Centre, 2008Google Scholar
- 17.Connock M, Juarez-Garcia A, Frew E, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1. Health Technol Assess 2006; 10: iii–113Google Scholar
- 25.Italian Medicines Agency. Post-marketing surveillance programme [online]. Available from URL: http://monitoraggio-farmaci.agenziafarmaco.it [Accessed 2010 Feb 16]